{
    "root": "538b7d03-c464-465d-b690-9701c14cf580",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Loxapine",
    "value": "20250226",
    "ingredients": [
        {
            "name": "Loxapine Succinate",
            "code": "X59SG0MRYU"
        },
        {
            "name": "Silicon Dioxide",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "Hypromellose, Unspecified",
            "code": "3NXW29V3WO"
        },
        {
            "name": "Lactose Monohydrate",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "Magnesium Stearate",
            "code": "70097M6I30"
        },
        {
            "name": "Titanium Dioxide",
            "code": "15FIX9V2JP"
        },
        {
            "name": "Fd&C Blue No. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "Fd&C Yellow No. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "Shellac",
            "code": "46N107B71O"
        },
        {
            "name": "Ferrosoferric Oxide",
            "code": "XM0M87F357"
        },
        {
            "name": "Butyl Alcohol",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "Propylene Glycol",
            "code": "6DC9Q167V3"
        },
        {
            "name": "Fd&C Blue No. 2--Aluminum Lake",
            "code": "4AQJ3LG584"
        },
        {
            "name": "Fd&C Blue No. 1 Aluminum Lake",
            "code": "J9EQA3S2JM"
        },
        {
            "name": "D&C Yellow No. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "Fd&C Red No. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "Ferric Oxide Yellow",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "loxapine capsules indicated treatment schizophrenia . efficacy loxapine schizophrenia established enrolled newly hospitalized chronically hospitalized acutely ill schizophrenic patients subjects .",
    "contraindications": "loxapine administered , usually divided doses , two four times day . daily ( terms base equivalents ) adjusted individual patient 's needs assessed severity symptoms previous history response antipsychotic drugs .",
    "warningsAndPrecautions": "loxapine capsules , usp available following strengths : loxapine succinate , usp 6.8 mg equivalent 5 mg loxapine , black ink , hard shell capsules size 2 , opaque , dark green body cap imprinted `` e525 `` cap body , supplied bottles 100 ndc # 64850-890-01. loxapine succinate , usp 13.6 mg equivalent 10 mg loxapine , black ink , hard shell capsules size 2 , opaque , yellow cap dark green body imprinted `` e526 `` cap body supplied bottles 100 ndc # 64850-891-01. loxapine succinate , usp 34.0 mg equivalent 25 mg loxapine , black ink , hard shell capsules size 2 , opaque , light green cap dark green body imprinted `` e527 `` cap body , supplied bottles 100 ndc # 64850-892-01. loxapine succinate , usp 68.0 mg equivalent 50 mg loxapine , black ink , hard shell capsules size 2 , opaque , light blue cap dark green body imprinted `` e528 `` cap body , supplied bottles 100 ndc # 64850-893-01. store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . dispense tight container defined usp , child-resistant closure , required . manufactured : elite laboratories , inc. northvale , nj 07647 usa in0537 revised 02/25",
    "adverseReactions": "loxapine contraindicated comatose severe drug-induced depressed states ( alcohol , barbiturates , narcotics , etc . ) . loxapine contraindicated individuals known hypersensitivity dibenzoxazepines .",
    "indications_original": "Loxapine capsules are indicated for the treatment of schizophrenia. The efficacy of loxapine in schizophrenia was established in clinical studies which enrolled newly hospitalized and chronically hospitalized acutely ill schizophrenic patients as subjects.",
    "contraindications_original": "Loxapine is administered, usually in divided doses, two to four times a day. Daily dosage (in terms of base equivalents) should be adjusted to the individual patient's needs as assessed by the severity of symptoms and previous history of response to antipsychotic drugs.",
    "warningsAndPrecautions_original": "Loxapine Capsules, USP are available in the following strengths: \n                     Loxapine succinate, USP 6.8 mg equivalent to 5 mg loxapine, black ink, hard shell capsules Size 2, opaque, with dark green body and cap imprinted with \"E525\" on cap and body, are supplied in bottles of 100 NDC# 64850-890-01. \n                     Loxapine succinate, USP 13.6 mg equivalent to 10 mg loxapine,black ink, hard shell capsules Size 2, opaque, yellow cap and dark green body imprinted with \"E526\" on cap and body are supplied in bottles of 100 NDC# 64850-891-01. \n                     Loxapine succinate, USP 34.0 mg equivalent to 25 mg loxapine, black ink, hard shell capsules Size 2, opaque, with light green cap and dark green body imprinted with \"E527\" on cap and body, are supplied in bottles of 100 NDC# 64850-892-01. \n                     Loxapine succinate, USP 68.0 mg equivalent to 50 mg loxapine,black ink, hard shell capsules Size 2, opaque, with light blue cap and dark green body imprinted with \"E528\" on cap and body, are supplied in bottles of 100 NDC# 64850-893-01. \n                     Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature]. Dispense in a tight\u00a0container as defined in the USP, with a child-resistant closure, as required. \n                     Manufactured by: Elite Laboratories, Inc. Northvale, NJ 07647 USA \n                     IN0537 \n                     Revised 02/25",
    "adverseReactions_original": "Loxapine is contraindicated in comatose or severe drug-induced depressed states (alcohol, barbiturates, narcotics, etc.). \n                     Loxapine is contraindicated in individuals with known hypersensitivity to dibenzoxazepines."
}